BioMarin's PKU treatment gets FDA fast-track review

01/30/2006 | (India)

The FDA has granted fast-track review status for BioMarin's Phenoptin for phenylketonuria, an oral small molecule therapeutic currently in phase III development. The company's CEO said the decision reflects the FDA's recognition that PKU "is a serious disease and unmet medical need."

View Full Article in: (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI